In this Host Rx episode, Dr. O examines a critical reality in addiction care: access gaps.
Medications for Opioid Use Disorder (MOUD), including buprenorphine, reduce all-cause mortality by approximately 50%. The evidence is clear. Yet in the United States, who receives these medications often depends on race, income, insurance status, and geography.
What This Episode Covers
- Racial disparities in buprenorphine prescribing.
- Geographic inequities and treatment deserts.
- Medicaid expansion and insurance barriers.
- Adolescent access gaps.
- Telehealth reforms and post-COVID regulatory changes.
- Structural determinants driving opioid mortality.
Grounded in peer-reviewed research and national policy analysis, this episode is designed for clinicians, policymakers, advocates, public health professionals, researchers, and trainees in psychiatry and addiction medicine, as well as anyone who wants to understand why zip code should not determine survival.
Featured Research
- Lagisetty et al., 2019. Buprenorphine Treatment Divide. JAMA Psychiatry. -
-Krawczyk et al., 2022. Policy Impact on Buprenorphine Access. JAMA Network Open.
-Goedel et al., 2021. Structural Determinants of Treatment Access. American Journal of Psychiatry.
-Samples et al., 2022. Telehealth and Buprenorphine Access. Health Affairs.
-Williams et al., 2023 .Treatment Inequities and Policy Reform. Lancet Psychiatry.
-Priest et al., 2022. Adolescent Treatment Access. Journal of Adolescent Health.
-Clinical guidance: SAMHSA and CDC.
Episode Chapters
00:00 Welcome to Transformed Minds
01:27 Why Access Matters
04:11 Research on Treatment Gaps
07:07 Clinician Pipeline and Policy
11:16 Frameworks and Care Models
12:31 Buprenorphine vs Methadone Systems
16:07 Geography, Youth, and Trauma
20:04 Case Study: Marcus
22:58 How Buprenorphine Works
25:50 Access Is the Treatment
27:35 Screen for Structural Barriers
30:55 Final Call to Advocate
Because where you live should not determine whether you survive.